Lab tests of e-cigarettes demonstrate cellular harm
January 01, 2016
Preclinical data based on experiments in mice suggest the promise of a novel drug directed against a novel target in malignant mammary tumors. The work excites researchers because in mouse models of human metastatic breast cancer, it has produced 'differentiation of an aggressive primary tumor, redirecting it from a highly proliferative state, and reducing its metastatic activity by 70 percent.' Both the drug and its target are nucleic acids.
Leave a comment